MAPK1 and familial pancreatic carcinoma: A recent study focused on directly targeting ERK as a treatment for pancreatic cancer identified the degradation of the MYC oncoprotein and the induction of a senescence-like phenotype as the predominant growth suppression mechanism of ERK inhibitors [71].